Bioniche Life Sciences Inc., of Belleville, Ontario, said it received guidance from the FDA providing regulatory clarity and permitting the submission of a biologics license application for mycobacterial cell wall-nucleic acid complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guerin refractory high-grade non-muscle invasive bladder cancer based on existing clinical data.